Purines are potentially a highly effective biomarker of stroke as they are released at the very onset of a stroke
Stroke is a higly complex condition, clinicians need to be confident in their diagnosis as treatment is not without risk.
Stroke diagnosis is currently made by clinical judgement, as objective analytical tests are unavailable in the immediate period after symptom onset. The diagnosis can be subject to uncertainty, which often results in delayed intervention and consequently poorer patient outcomes.
A clinically useful point of care test for stroke requires measurement of a rapidly produced biomarker to inform clinical decisions in the key early stages, where it would be most useful in ensuring complete recovery.